Drug Profile
Research programme: xanthine oxidase inhibitors - Astellas
Alternative Names: AS 186278-NA; AS 191293-00; AS 1924601-00; AS 1931018-00Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Carboxylic acids; Nitriles
- Mechanism of Action Xanthine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Gout; Hyperuricaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Gout in Japan (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hyperuricaemia in Japan (PO)
- 26 Aug 2010 Research programme: xanthine oxidase inhibitors - Astellas is available for licensing as of 26 Aug 2010. http://www.astellas.com/en/index.html